• Home
  • About
  • Science
  • Pipeline
  • Team
  • News
  • Contact
  • More
    • Home
    • About
    • Science
    • Pipeline
    • Team
    • News
    • Contact
  • Home
  • About
  • Science
  • Pipeline
  • Team
  • News
  • Contact

Halo's lead program, H01, is a small-molecule first-in-class inhibitor of HA synthesis under development for conditions including pulmonary hypertension, IPF, and primary sclerosing cholangitis.  A Phase I study was recently completed at Stanford University.


Our pipeline of proprietary compounds targeting extra cellular matrix editing are in various stages of discovery and preclinical development.  Our partnership with Stanford University and the Paul Bollyky Lab serves as the anchor for drug candidate discovery and lead optimization. 

The Foundation

The Foundation

The Foundation

Extracellular matrix editing represents a novel, differentiated mechanism with potential to transform disease states 

Our Science

The People

The Foundation

The Foundation

Halo is a team of leaders in extracellular matrix biology and drug development. We are closely connected to Stanford University's unparalleled ecosystem of drug discovery.

Our Team

Learn More

The Foundation

Learn More

Learn more about Halo, our pipeline, and extracellular matrix editing

Contact Us

Copyright © 2022 Halo Biosciences - All Rights Reserved.